With its own COVID-19 vaccine trial on pause, Sanofi will produce 12 million doses of Johnson & Johnson’s candidate

Sanofi.
(Image credit: YANN SCHREIBER/AFP via Getty Images)

While its own COVID-19 vaccine candidate faces trial delays, French drug maker Sanofi will use its vaccine manufacturing plant in Marcy L'Etoike, France, to formulate and fill vials with Johnson & Johnson's single-dose shot. The goal, Sanofi said, is to produce about 12 million doses in its facility.

The companies are considered rivals, but Sanofi CEO Paul Hudson said the company is "stepping forward to show solidarity" amid the coronavirus pandemic, even as it remains focused on eventually moving forward with its own trials.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us
Tim O'Donnell

Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.